813. Interactive Panelist
Session: Interactive Session: Approach to Clinical Syndromes in the Transplant Patient
Saturday, October 22, 2011: 8:15 AM
Room: Grand Ballroom (East-West)


Corey Casper, MD, MPH, FIDSA, Fred Hutchinson Cancer Research Center, Seattle, WA

Dr. Casper received his medical degree from Cornell University Medical College in 1997, followed by an internal medicine residency at the University of California, San Francisco. Moving onto the University of Washington, Dr. Casper completed a Masters in Public Health degree in 2002 and his Infectious Disease fellowship training. He then joined the faculty in 2003. He currently is an Associate Professor of Medicine and an Adjunct Associate Professor of Epidemiology and Global Health at the University of Washington. Hes is also an Associate Member at the Fred Hutchinson Cancer Research Center in the Vaccine and Infectious Disease and Public Health Science Divisions. Dr. Casper divides his time between research, teaching and clinical care. At the Seattle Cancer Care Alliance, he directs the Infection Control Program, which has developed novel methods for the prevention of respiratory virus infections among patients with impaired immunity and new methods for tracking and reducing healthcare-associated infections. At the Fred Hutchinson Cancer Research Center, he directs the Uganda Program on Cancer and Infectious Diseases. This program, in partnership with the Uganda Cancer Institute in Kampala, conducts research aimed at identifying how infections which cause cancer are acquired, defining strategies for the treatment and prevention of infection-related cancer, and training African and US health care providers to be the next generation of cancer researchers and care providers. In Seattle, Dr. Casper cares for patients at the Seattle Cancer Care Alliance and Harborview Medical Center, where he specializes in infections among persons with impaired immunity due to HIV or cancer.



Previous Presentation | Next Presentation >>

Findings in the abstracts are embargoed until 12:01 a.m. EST Thursday, Oct. 20 with the exception of research findings presented at IDSA press conferences.